Reactivation of retinopathy of prematurity after bevacizumab injection. - Wikidata - wikimedia - TriplyDB

Reactivation of retinopathy of prematurity after bevacizumab injection.

Reactivation of retinopathy of prematurity after bevacizumab injection.

http://www.wikidata.org/entity/Q34227463

about

Pharmacologic interventions for the prevention and treatment of retinopathy of prematurity Screening and Treatment in Retinopathy of Prematurity Asymmetric Outcomes of Type 1 Retinopathy of Prematurity after Bilateral Intravitreal Ranibizumab Treatment.Adenosine receptors and caffeine in retinopathy of prematurity.Insulin-like growth factor-1 and anti-vascular endothelial growth factor in retinopathy of prematurity: has the time come?[Current therapeutic options in retinopathy of prematurity].Serious adverse events and visual outcomes of rescue therapy using adjunct bevacizumab to laser and surgery for retinopathy of prematurity. The Indian Twin Cities Retinopathy of Prematurity Screening database Report number 5.Hyperoxia causes regression of vitreous neovascularization by downregulating VEGF/VEGFR2 pathway.Late recurrence of retinopathy of prematurity after treatment with both intravitreal bevacizumab and laser.Intravitreal injection of bevacizumab for retinopathy of prematurity.Intravitreal injection of bevacizumab for retinopathy of prematurity in an infant with peters anomaly Vascular endothelial growth factor antagonist therapy for retinopathy of prematurity Posterior pole sparing laser photocoagulation combined with intravitreal bevacizumab injection in posterior retinopathy of prematurity.Retinopathy of prematurity: New developments bring concern and hope.A Systematic Review and Meta-Analysis on the Safety of Vascular Endothelial Growth Factor (VEGF) Inhibitors for the Treatment of Retinopathy of Prematurity.Serial evaluation of retinal vascular changes in infants treated with intravitreal bevacizumab for aggressive posterior retinopathy of prematurity in zone I.Low dose versus conventional dose of intravitreal bevacizumab injection for retinopathy of prematurity: a case series with paired-eye comparison.Regression Rates Following the Treatment of Aggressive Posterior Retinopathy of Prematurity with Bevacizumab Versus Laser: 8-Year Retrospective Analysis.Treatment of type I ROP with intravitreal bevacizumab or laser photocoagulation according to retinal zone.Comparison of Bevacizumab, Ranibizumab, and Laser Photocoagulation in the Treatment of Retinopathy of Prematurity in Turkey.Combination of Intravitreal Injection of Ranibizumab and Photocoagulation for the Treatment of Aggressive Posterior Retinopathy of Prematurity with Vitreous Hemorrhage.Outcome of solid-state 532 nm green laser in high-risk retinopathy of prematurity at a tertiary care centre in India.Anti-VEGF therapy in the management of retinopathy of prematurity: what we learn from representative animal models of oxygen-induced retinopathy Adenosine A1 Receptors Selectively Modulate Oxygen-Induced Retinopathy at the Hyperoxic and Hypoxic Phases by Distinct Cellular Mechanisms.Involution patterns of retinopathy of prematurity after treatment with intravitreal bevacizumab: implications for follow-up.Emerging roles for antiangiogenesis factors in management of ocular disease.Retinopathy of prematurity: An update on screening and management Anti-VEGF antibody leads to later atypical intravitreous neovascularization and activation of angiogenic pathways in a rat model of retinopathy of prematurity Short hairpin RNA-mediated knockdown of VEGFA in Müller cells reduces intravitreal neovascularization in a rat model of retinopathy of prematurity.Retinal expression of small non-coding RNAs in a murine model of proliferative retinopathy.Quantitative analyses of retinal vascular area and density after different methods to reduce VEGF in a rat model of retinopathy of prematurity.Targeting Müller cell-derived VEGF164 to reduce intravitreal neovascularization in the rat model of retinopathy of prematurity.Mechanisms and management of retinopathy of prematurity.Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature VEGFA activates erythropoietin receptor and enhances VEGFR2-mediated pathological angiogenesis Clinical Management of Recurrent Retinopathy of Prematurity after Intravitreal Bevacizumab Monotherapy.Advances in understanding and management of retinopathy of prematurity.An Update on Retinopathy of Prematurity (ROP).Ocular Adverse Effects of Intravitreal Bevacizumab Are Potentiated by Intermittent Hypoxia in a Rat Model of Oxygen-Induced Retinopathy.Intravitreal low-dosage bevacizumab for retinopathy of prematurity.

P2860

Q26772889-114D2213-B0E2-489B-A909-7EE0217D19E6 Q28082541-C5AE7F76-D5D9-408B-875A-F5CC4FB58C72 Q33561241-9062061F-DA14-4CE3-A544-B584F84C07F1 Q33860622-BB782440-40FB-4CD5-A168-CAEB6DE3E241 Q34339456-D4343CA5-CB10-401A-824A-3FDF9DE5EEE8 Q34501395-D045D788-BC2F-43F9-824C-777D135A2C5C Q34523362-C2834EB3-7C4D-41F2-83A0-8912C91BFE43 Q34544365-0C90DA40-56D7-4FEC-A0AD-CBA26FB79103 Q34778243-E004CF62-B83A-420E-8A17-FEBEF88BC9AE Q35102460-5C86D00D-7F6E-4BD1-B69B-DAE639E0D4AB Q35435581-E66231CC-5BB0-4AD6-AA93-44A29B912401 Q35473907-B9E89DC5-4DB4-4D37-AC48-2472C10AA03D Q35547787-F306A6C0-E799-47AE-8D63-F4208D8042EC Q35574624-53587A24-0105-46D6-86A2-3A50E16DBDB4 Q35665701-1E53046C-FEF0-487F-ACFD-1E1BD1D0DDC1 Q35846321-C90DC9EA-116D-427B-928F-200EFBB363FA Q35969307-5A00F182-81CF-4573-B6CC-E7DFB41CEF9C Q35984783-CB307189-CDDB-4135-85B2-2644760C1C28 Q36052210-4D1ADF8A-8535-4E99-8E5D-10468A334883 Q36078573-E469E5B5-EDC7-4251-8FB6-0DAA3E9ACBD5 Q36245132-0B22B633-0696-40FC-BB54-C11D4A1B15BE Q36282110-726C1579-D812-4F59-A8D3-04640F15EC58 Q36379513-C24B3221-B59F-476E-B576-2ACF4F948DD5 Q36424969-16A41AD3-5A0F-44F1-B8E2-DF74DF2D4B57 Q36686806-DEAB19C7-2A7A-486C-90E9-14F2547DC3DF Q36696513-79F361DA-B7BD-4470-BE2B-7CF14926E015 Q36728908-D3F4EC83-E013-4F71-AFF5-C7D717742F20 Q36752978-77B8FFF6-F206-4FDE-91B1-2E702E1287CC Q37149035-93237F2A-8EB7-4BEC-BE14-38E4D19F47C4 Q37274155-89369A4C-B588-4BC0-8434-DF93CEC86A11 Q37561227-D5C72CFD-3EB1-4EE5-AC3D-FBFDADDFD3F7 Q37577214-F4EA6AF1-1AD2-42FD-BA42-DD1C7DF0325D Q38069895-9A958CEE-A1EB-4EA6-B38D-38D8DA619905 Q38110731-DB0EB565-6CF3-4426-9B2B-511F4E25DC1C Q38560836-CDF66427-59CD-4BB1-A309-F35776F154C6 Q38848653-DA689E8B-1EC5-4F23-8B11-B5FB9F4B07DC Q39052915-C275DD20-87E5-4C88-BA7D-2787B42170BA Q39413013-BD20C501-194F-438F-BB52-E2E9AD475B4A Q41100793-763D36B4-F241-4F9B-AA63-5DB08E582849 Q45147023-25E1D2DC-B4EB-4EC1-8596-81C94668C3D4

P2860

Reactivation of retinopathy of prematurity after bevacizumab injection.

http://www.wikidata.org/entity/Q34227463

description

2012 nî lūn-bûn

@nan

2012 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Reactivation of retinopathy of prematurity after bevacizumab injection.

@ast

Reactivation of retinopathy of prematurity after bevacizumab injection.

@en

Reactivation of retinopathy of prematurity after bevacizumab injection.

@nl

type

label

Reactivation of retinopathy of prematurity after bevacizumab injection.

@ast

Reactivation of retinopathy of prematurity after bevacizumab injection.

@en

Reactivation of retinopathy of prematurity after bevacizumab injection.

@nl

prefLabel

Reactivation of retinopathy of prematurity after bevacizumab injection.

@ast

Reactivation of retinopathy of prematurity after bevacizumab injection.

@en

Reactivation of retinopathy of prematurity after bevacizumab injection.

@nl

P1433

Q34227463-A197589B-A618-4D4A-9C60-7309DEB2F472

P1476

Q34227463-0E3EC198-1047-4516-987D-8C3F9E5D13AD

P2093

Q34227463-53DE8C15-2883-45F6-ACB6-319371644980

Q34227463-7E697DE1-2D36-436F-BE53-EE78436B7762

Q34227463-A67781FC-53DD-4078-AE13-50577B28D040

Q34227463-A89A6609-D762-4A3A-BE13-C4C7476E7B0C

Q34227463-AF2B245A-BA22-4528-B99F-E19F97AFBBE4

Q34227463-E1CC307F-5786-4498-9A04-A850DCF8FB5C

P304

Q34227463-B967B022-6E08-404E-9A9B-121631761C0F

P31

Q34227463-CE579F65-35EB-496A-9547-F1519831BDE5

P356

Q34227463-A84441E2-32A5-4AC0-BC98-0FBD9FC3E116

P407

Q34227463-1C2CD2C0-70C8-48DC-B8C3-AC38BAFCDD78

P433

Q34227463-4068CF63-855E-4320-A77C-C504DDBBD606

P478

Q34227463-AB191C00-7057-48BC-B90C-EB0E56D8206D

P577

Q34227463-6E99D767-11F7-4650-A17D-F34B56391142

P698

Q34227463-56837299-2712-4DE2-BD2B-65F0C0E1DD6F

P921

Q34227463-535AB950-04B4-4947-BE42-3704D3A51EF4

P356

ARCHOPHTHALMOL.2012.592

P1433

JAMA Ophthalmology

P1476

Reactivation of retinopathy of prematurity after bevacizumab injection.

@en

P2093

Jennifer Hu

http://www.w3.org/2001/XMLSchema#string

John M Galasso

http://www.w3.org/2001/XMLSchema#string

Michael J Shapiro

http://www.w3.org/2001/XMLSchema#string

Michael P Blair

http://www.w3.org/2001/XMLSchema#string

Rashmi Kapur

http://www.w3.org/2001/XMLSchema#string

Steven J Lichtenstein

http://www.w3.org/2001/XMLSchema#string

P304

1000-1006

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1001/ARCHOPHTHALMOL.2012.592

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

130

http://www.w3.org/2001/XMLSchema#string

P577

2012-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22491394

http://www.w3.org/2001/XMLSchema#string

P921